Pacira BioSciences: 2024 record rev $701M, GAAP net loss $99.6M on $163M impairment; FY2025 rev guide $725M-$765M

Pacira BioSciences, Inc.

2024-FY EPS reported -$2.15 revenue$700,966,000

Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.
Full-year GAAP net loss $99.6M ($2.15 loss/share) includes $163.2M goodwill impairment; adjusted EBITDA $223.9M (+4%).
Non-GAAP net income $157.7M ($3.20 diluted); Q4 non-GAAP net income $44.3M ($0.91 diluted).
Acquired remaining 81% of GQ Bio for ~$32M net; adds genetic medicine platform, eliminates future milestones.
FY2025 guidance: rev $725-765M, non-GAAP gross margin 76-78%, R&D $90-105M, SG&A $290-320M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.